Consistently, losartan treatment or shRNA-mediated receptor silencing significantly reduced tumor burden in an immunodeficient xenograft model, suggesting a potential role for targeting AGTR1 in LAM and other manifestations of TSC. Here, AGTR1 is linked to lymphangioleiomyomatosis.